

**P1252**

**Poster Session V**

**Immunology, vaccination and host defences**

**STREPTOCOCCUS PNEUMONIAE ANTIBODY TITERS FOR THE SEROTYPES CIRCULATING IN CUBA EVALUATED ON CLINICAL TRIAL SUBJECTS.**

**N. González García<sup>1</sup>, V. Echemendía<sup>1</sup>, L. Rodríguez<sup>1</sup>, Y. Soroa<sup>1</sup>, A. Garcés<sup>1</sup>, D. García<sup>1</sup>, Y. Valdés<sup>1</sup>, D. Santana<sup>1</sup>, S. Rosell<sup>1</sup>, B. Paredes<sup>1</sup>**

<sup>1</sup>Clinical Trials, Centro de Química Biomolecular, Havana, Cuba

Some of the first clinical trials in Cuba for a new heptavalent conjugate vaccine against *Streptococcus pneumoniae*, included the immunological evaluation of 55 subjects (40 adults aged 18-35 years old and 15 children aged 4-5 years old) which data were obtained in baseline immune status to assess opsonophagocytic antibody titers pre-immunization against *Streptococcus pneumoniae* serotypes circulating during the last decade in the country and there are contained in the Cuban vaccine: 1, 5, 6B, 14, 18C, 19F and 23F. Opsonophagocytosis assay (OPA) was used for testing the serum. The tests were considered positive for titers higher than or equal to 1:8. The 33.9% of the subjects had opsonophagocytic antibodies for serotype 14, 28.0% for 19F, 12.7% for 23F and 9.4% for 6B. Lower percentage was detected for serotypes 1 and 18C. No opsonophagocytic antibodies for serotypes 5 were found. Most part of studied group has not detectable antibodies titers for the *Streptococcus pneumoniae* serotypes circulating in Cuba. These results suggest that it's necessary the introduction of a vaccine against the most common pneumococcal serotypes in this region to get an appropriate immunity of these population groups.